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Abstract
Background: The negative feedback system is an important physiological regulatory mechanism controlling
angiogenesis. Soluble vascular endothelial growth factor (VEGF) receptor-1 (sFlt-1), acts as a potent endogenous
soluble inhibitor of VEGF- and placenta growth factor (PlGF)-mediated biological function and can also form
dominant-negative complexes with competent full-length VEGF receptors.
Methods and results: Systemic overexpression of VEGF-A in mice resulted in significantly elevated circulating sFlt-
1. In addition, stimulation of human umbilical vein endothelial cells (HUVEC) with VEGF-A, induced a five-fold
increase in sFlt-1 mRNA, a time-dependent significant increase in the release of sFlt-1 into the culture medium and
activation of the flt-1 gene promoter. This response was dependent on VEGF receptor-2 (VEGFR-2) and
phosphoinositide-3’-kinase signalling. siRNA-mediated knockdown of sFlt-1 in HUVEC stimulated the activation of
endothelial nitric oxide synthase, increased basal and VEGF-induced cell migration and enhanced endothelial tube
formation on growth factor reduced Matrigel. In contrast, adenoviral overexpression of sFlt-1 suppressed
phosphorylation of VEGFR-2 at tyrosine 951 and ERK-1/-2 MAPK and reduced HUVEC proliferation. Preeclampsia is
associated with elevated placental and systemic sFlt-1. Phosphorylation of VEGFR-2 tyrosine 951 was greatly
reduced in placenta from preeclamptic patients compared to gestationally-matched normal placenta.
Conclusion: These results show that endothelial sFlt-1 expression is regulated by VEGF and acts as an autocrine
regulator of endothelial cell function.
Background
Vascular endothelial growth factor-A (VEGF-A) is a
multifunctional cytokine induced by hypoxic stress [1].
It plays a pivotal role in many aspects of embryonic car-
diovascular development, including formation of blood
vessels, cardiac morphogenesis, and development of the
nervous system [2-6]. Loss and gain of function studies
in mice indicate that VEGF-A levels have to be main-
tained within a narrow range to ensure proper cardio-
vascular development and embryo survival [7-9]. It has
been shown that the effects of VEGF-A can be deleter-
ious if uncontrolled. Over-expression of VEGF in experi-
mental animals increases the leakiness of blood vessels,
which may lead to severe edema, loss of limb and death
[10,11]. Excess VEGF-A expression in skeletal muscle
results in the induction of vascular tumors (hemangio-
mas) [12-14], whereas loss of VEGF-A activity due to
increased production of its natural antagonist, sFlt-1
(soluble VEGF receptor-1/sVEGFR-1), as in preeclamp-
sia, reduces angiogenesis [15]. Thus, homeostasis
requires mechanisms to regulate the functional activity
of VEGF-A.
Soluble Flt-1 is generated by alternative splicing of the
f m s - l i k et y r o s i n ek i n a s e( flt-1) gene [16], and binds to
all isoforms of VEGF-A and placenta growth factor
(PlGF) with high affinity [16,17]. It acts as a potent solu-
ble inhibitor of both VEGF-A and PlGF-mediated biolo-
gical activities [18] and can also form dominant-negative
complexes with competent full-length VEGF receptors
[16]. In pregnancies complicated with preeclampsia,
sFlt-1 levels are elevated [15,19-21]. Maternal serum
levels of sFlt-1 are elevated five weeks prior to the onset
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any medium, provided the original work is properly cited.of preeclampsia [22], supporting the premise that sFlt-1
is a key factor responsible for the clinical manifestation
of this disorder [23]. The demonstration that sFlt-1 is
fundamental to the clinical onset of preeclampsia [24]
highlights the importance of understanding the intracel-
lular mechanism underlying its regulation and release in
endothelial cells. Recently it was shown that autocrine
VEGF signaling is required for vascular homeostasis
[25]. Here we demonstrate that endothelial sFlt-1
expression is regulated by VEGF and sFlt-1 is an auto-
crine regulator of endothelial cell function.
Materials and methods
Reagents
Recombinant growth factors were purchased from RELIA-
Tech (Brauschweig, Germany). Rabbit polyclonal antibo-
dies against phospho- endothelial nitric oxide synthase
(eNOS) at serine-1177 (p-eNOS
Ser1177), phospho-ERK-1/-
2 MAPK and phospho-VEGF receptor-2 (VEGFR-2) tyro-
sine-951 antibodies were purchased from Calbiochem
(Nottingham, UK). Small inhibitory RNAs (siRNA) and
oligonucleotide primers were purchased from Eurogentec
(Southampton, UK). Luciferase reporter assay and cDNA
synthesis kits were from Promega (Southampton, UK). All
other cell culture reagents and chemicals were obtained
from Sigma Aldrich (Poole, UK).
Placental tissues
Human placental tissue was obtained from normal preg-
nancies and gestationally-matched pregnancies compli-
cated by preeclampsia. Preeclampsia was defined as
blood pressure > 140/90 mm Hg on at least two conse-
cutive measurements and proteinuria of at least 300 mg
per 24 hours. Informed consent was obtained from the
patients and the study had the approval of the South
Birmingham Ethical Committee (Birmingham, UK).
Cell Culture
Primary human umbilical vein endothelial cells
(HUVEC) were isolated and cultured as described [26].
Cells were used at passage two or three for experiments
and serum-starved in endothelial cell serum-free med-
ium (Gibco-BRL, UK) supplemented with 0.2% bovine
serum albumin for 24 hours prior to stimulation.
Adenoviral gene transfer
The recombinant, replication-deficient adenoviruses
encoding sFlt-1 (Ad-sFlt-1) VEGF (Ad-VEGF) and
PTEN (Ad-PTEN) were used as described previously
[27-29].
Quantitative Real-Time PCR
Sample preparation and real-time PCR was performed as
described previously [30]. Briefly, mRNA was prepared
using TRIzol and DNase-1 digestion/purification on
RNAeasy columns (Qiagen), and reverse transcribed with
the cDNA Synthesis Kit (Promega). Triplicate cDNA
samples and standards were amplified in SensiMix con-
taining SYBR green (Quantace) with primers specific for
sFlt-1 [31]. The mean threshold cycle (CT) was normal-
ized to b-actin and expressed relative to control.
siRNA knock-down of sFlt-1
Two siRNA sequences to the unique 3’ sequence of sFlt-
1 (sFlt-1 A sense: 5’-TAACAGUUGUCUCAUAUCAtt-3’
and antisense: 5’-UGAUAUGAGACAACUGUUAtt-3’;
sFlt-1 B sense: 5’-UCUCGGAUCUCCAAAUUUAtt-3’
and antisense 5’-UAAAUUUGGAGAUCCGAGAtt-3’)
were designed using the Dharmacon siDESIGN tool
[32]. HUVEC (~ 1 × 10
6 cells) were electroporated with
~3μg of sFlt-1, or a universal control siRNA (Dharma-
con) using the HUVEC kit II and Amaxa nucleofector
(Amaxa GmbH, Cologne, Germany) as described [30].
Transduction of chimeric VEGF Receptors in HUVEC
A chimeric VEGF/epidermal growth factor (EGF) receptor
comprising the intracellular and transmembrane domains
of VEGFR-2 fused to the extracellular domain of the
human EGF receptor [33]. EGF does not bind to VEGF
receptors, therefore, it does not activate the endogenous
VEGF receptors. EGDR and its tyrosine-to-phenylalanine
mutants (EGDR-Y951F) were generated and cloned into
the pMMP retroviral vector, and retrovirus-containing cell
supernatant was harvested and used immediately to infect
HUVEC [33]. Following 16 hours of incubation, the med-
ium was replaced with fresh growth medium and the
HUVEC were used 48 hours after infection.
Nitric oxide (NO) Release
Total NO in conditioned media was assayed as nitrite,
the stable breakdown product of NO, using a Sievers
NO chemiluminescence analyzer (Analytix, Sunderland,
UK) as described previously [33].
Tube Formation Assay
The formation of capillary-like structures was examined
on growth factor-reduced Matrigel in 24-well plates as
described previously [33]. Tube formation was quanti-
fied by measuring the total tube length in five random
x200 power fields per well using a Nikon phase-contrast
inverted microscope with Image ProPlus image analysis
software (Media Cybernetics, Silver Spring, USA). Mean
total tube length was calculated from three independent
experiments performed in duplicate.
flt-1 gene promoter activity assay
A 1.3 Kb fragment of the human flt-1 gene correspond-
ing to -1214 to +155 bp relative to the first exon in the
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flt-1 promoter activity [34]. Briefly, porcine aortic
endothelial cells (PAEC) were transfected with the flt-1
promoter-reporter construct using Exgen 500 (Fermen-
tas, UK) and the cell lysates assayed as described pre-
viously [34].
Western Blotting
Cells lysates were immunoblotted as described pre-
viously [33]. Membranes were probed with rabbit poly-
clonal antibodies against phospho-eNOS-Ser
1177,a n t i -
ERK-1/-2 or anti-VEGFR-2 phosphotyrosine-951 at 4°C
overnight. Proteins were visualised using the ECL detec-
tion kit (Amersham-Pharmacia, UK).
sFlt-1 ELISA
Soluble Flt-1 (sFlt-1) levels in culture supernatants were
measured as previously described [30].
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were used for
immunohistochemistry as previously described [15].
Statistical analysis
All data are expressed as mean ± SEM. Statistical com-
parisons were performed using one-way ANOVA fol-
lowed by the Student-Newman-Keuls test as
appropriate. Statistical significance was set at a value of
p < 0.05.
Results and Discussion
VEGF-A stimulates sFlt-1 release
To evaluate the capacity of VEGF-A to regulate the
secretion of its negative regulator, sFlt-1, HUVEC were
incubated with VEGF-A and the conditioned media
assayed for sFlt-1 by ELISA. VEGF-A stimulated a con-
centration and time dependent increase in the release of
sFlt-1 from HUVEC that reached a maximum at 20 ng/
ml and 48 hours, respectively (Figure 1a and 1b). Con-
sistent with these findings, qPCR revealed a greater than
five-fold increase in sFlt-1 mRNA after 22 hours of
VEGF-A stimulation (Figure 1c). In addition, VEGF-A
induced flt-1 gene promoter activity in porcine aortic
endothelial cells transfected with a flt-1 promoter luci-
ferase construct (Figure 1d). Incubation of cells with
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Figure 1 VEGF stimulates sFlt-1 release from endothelial cells in vitro, and in vivo. (a) VEGF stimulated sFlt-1 release from HUVEC in a
concentration-dependent manner. sFlt-1 was measured, in the culture medium, by ELISA, following a 24-hour incubation. (b) Time course of
VEGF (20 ng/ml) induced sFlt-1 release from HUVEC. (c) VEGF induced an increase in sFlt-1 mRNA levels in HUVEC as determined by qPCR and,
(d) flt-1 promoter activity in porcine aortic endothelial cells by luciferase assay. (e) Cyclohexamide (10 μg/ml) inhibits VEGF-induced sFlt-1 protein
synthesis after 24 hours of treatment. (f) Mouse plasma levels of sFlt-1 five days post intravenous injection with an adenovirus encoding VEGF
(Ad-VEGF) or control (Ad-bgal). Data are expressed as mean (± SEM) or representative of three or more independent experiments performed in
triplicate. **P < 0.01; ***P < 0.001 vs. control.
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Page 3 of 8cycloheximide abrogated the VEGF-A induced response
(Figure 1e), which coupled with the fact that there is a
negligible release with VEGF-A after two hours of sti-
mulation, indicates that sFlt-1 secretion is due to de
novo protein synthesis and not release from intracellular
vesicles. Adenoviral-mediated overexpression of VEGF-
Ai nm i c ec a u s e da ne i g h t - f o l di n c r e a s ei nc i r c u l a t i n g
sFlt-1 levels (Figure 1f), demonstrating, in vivo,t h a ta n
increase in VEGF-A results in a concomitant rise in cir-
culating sFlt-1 levels, presumably to compensate for ele-
vated VEGF bioactivity.
Activation of VEGFR-2, mediates the release of sFlt-1
To identify the VEGF receptors involved in the release
of sFlt-1, HUVEC were stimulated with either VEGF-A
(binds VEGFR-1 and VEGFR-2), or PlGF-1 (binds
VEGFR-1) or VEGF-E (binds VEGFR-2). PlGF-1 showed
no effect on sFlt-1 release, whereas VEGF-E stimulated
similar levels of sFlt-1 release to those induced by
VEGF-A (Figure 2a), suggesting that release of sFlt-1 is
mediated by VEGFR-2. Preincubation of endothelial
cells with SU1498, a VEGFR-2 selective inhibitor,
blocked the VEGF-A induced sFlt-1 release (Figure 2b),
confirming the importance of this receptor for the
response.
VEGF stimulated sFlt-1 production, is mediated via PI3K
To investigate the role of the PI3K pathway in VEGF-A-
induced sFlt-1 release, PI3K activity was inhibited
through overexpression of PTEN (Phosphatase and Ten-
sin homolog deleted on chromosome Ten), which
dephosphorylates phosphatidylinositol 3,4,5-triphosphate
and has been shown to reduce VEGF-mediated signaling
and cellular function [28,35]. HUVEC were infected
overnight with an adenovirus encoding PTEN (PTEN
(wt)) or a control adenovirus (CMV) and stimulated
a b c
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Figure 2 VEGF-A-induced sFlt-1 release requires VEGFR-2 and the PI3K pathway. (a) sFlt-1 release from HUVEC 24 hours after incubation
with PlGF-1 (20 ng/ml), VEGF-A (20 ng/ml) and VEGF-E (20 ng/ml). (b) sFlt-1 release from HUVEC after incubation with SU1498 (10 μM), a VEGFR-
2 tyrosine kinase inhibitor, prior to addition of VEGF-A (20 ng/ml) for 24 hours. (c) sFlt-1 release from HUVEC infected with an adenovirus
encoding PTEN (PTEN (wt)) or control adenovirus (CMV) prior to stimulation with VEGF-A (20 ng/ml) for 24 hours. Western blot demonstrating
decreased PTEN expression in HUVEC infected with Ad-PTEN(wt) compared with Ad-CMV control (insert). (d) sFlt-1 release from HUVEC after
incubation with LY294002 (10 μM), a PI3K inhibitor, prior to addition of VEGF-A (20 ng/ml) for 24 hours. (e) LY294002 prevented the VEGF-A-
induced flt-1 promoter activity in porcine aortic endothelial cells, assayed by luciferase reporter assay. Data are expressed as mean (± SEM) or
representative of three or more independent experiments performed in triplicate. **P < 0.01 vs. control.
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Page 4 of 8with VEGF-A for 24 hours. Inhibition of PI3K activity
by PTEN overexpression led to a significant decrease in
sFlt-1 release (Figure 2c). Furthermore, pre-incubation
of HUVEC with LY294002, a pharmacological PI3K
inhibitor, also attenuated the VEGF mediated release of
sFlt-1 (Figure 2d) and of flt-1 gene promoter activity
(Figure 2e).
Loss of sFlt-1 promotes angiogenesis
Adenoviral-mediated overexpression of sFlt-1 in
HUVEC inhibited endothelial cell proliferation (Figure
3a) and MAP kinase ERK-1/-2 phosphorylation (Figure
3a insert). Subsequently, to test whether knockdown of
sFlt-1 would promote endothelial cell proliferation,
HUVEC were transfected with two synthetic siRNA
sequences targeted to the unique carboxyl-terminus
region of sFlt-1. sFlt-1 siRNA transfection resulted in a
substantial reduction in the release of sFlt-1 from
HUVEC after 24 hours (Figure 3b). Endothelial cell pro-
liferation was significantly increased (Figure 3c) and
interestingly, sFlt-1 knockdown also led to a concomi-
tant increase in VEGFR-2 phosphorylation at tyrosine
951 (Y951) (Figure 3d). In addition, sFlt-1 siRNA
increased both basal and VEGF-A-mediated endothelial
cell migration (Figure 4a) and tube formation on Matri-
gel (Figure 4b and 4c). VEGF stimulates eNOS activity
and NO release [23,36] to mediate angiogenesis [33,37],
thus we predicted that loss of sFlt-1 would increase
eNOS phosphorylation in HUVEC. Phosphorylation of
eNOS (ser1177) was significantly increased in cells lack-
ing sFlt-1 (Figure 4d). These data provide direct evi-
dence that sFlt-1 is itself a negative regulator of
endothelial function. It is likely that sFlt-1 sequesters
VEGF and PlGF to maintain a physiological steady state
until angiogenesis is required, at which point this system
must be overridden.
a b
AdE-gal Ad-sFlt1
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35

P
r
o
l
i
f
e
r
a
t
i
v
e
 
A
c
t
i
v
i
t
y
(
O
D
 
5
4
0
-
6
9
0
)
pErk1/2
E-actin
EGal sFlt-1
c
Control siRNA sFlt-1 siRNA
0
1
2
3
4
5
6
7
s
F
l
t
-
1
 
(
n
g
/
m
l
)
d
pVEGFR-2 (Y951)
VEGFR-2
E-actin
Control sFlt-1
siRNA
Control siRNA sFlt-1 siRNA
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
P
r
o
l
i
f
e
r
a
t
i
v
e
 
A
c
t
i
v
i
t
y
(
O
D
 
5
4
0
-
6
9
0
) **
Figure 3 sFlt-1 inhibits endothelial cell proliferation and VEGF receptor phosphorylation. (a) Cell proliferation after 48 hours of treatment
in HUVEC infected with an adenovirus encoding sFlt-1 (Ad-sFlt1) or b-galactosidase control (Ad-bGal). Western blot demonstrating decreased
Erk1/2 phosphorylation in HUVEC infected with Ad-sFlt-1 compared with Ad-b-gal control (insert). (b) Dramatic reduction of sFlt-1 release from
HUVEC 24 hours after transfection with sFlt-1 siRNA. (c) Cell proliferation after 48 hours in sFlt-1 siRNA transfected HUVEC. (d) Western blot
showing VEGF receptor-2 (VEGFR-2) phosphorylation at tyrosine 951 in HUVEC transfected with sFlt-1, or control siRNA. VEGFR-2 and b-actin
were used as a loading control. Data are expressed as mean (± SEM) or representative of three or more independent experiments performed in
triplicate. **P < 0.01 vs. control.
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Activation of VEGFR-2 leads to an increase in eNOS
expression and activation,[38] which is essential for
neovascularisation [37]. A recent study showed that
mutation of VEGFR-2 Y951 to phenylalanine caused a
significant reduction in VEGF-induced angiogenesis
[33]. As preeclampsia is associated with elevated pla-
cental [15] and circulating [22] sFlt-1 and placental
sFlt-1 inhibits angiogenesis [15], we speculated that
elevated free sFlt-1 would lead to a reduction of
VEGFR-2 phosphorylation in preeclamptic placenta.
Using the EGFR-chimeric receptor system we show
that mutation of Y951 to phenylalanine resulted in
over 50% reduction in NO release (Figure 5a) and
overexpression of sFlt-1 in endothelial cells abrogated
phosphorylation of VEGFR-2 Y951 (Figure 5b). To
assess whether VEGFR-2 phosphorylation was reduced
in preeclamptic placenta, that express elevated sFlt-1,
we undertook immunohistochemical analysis for phos-
p h o - V E G F R - 2Y 9 5 1 .O v e r a l l ,p h o s p h o r y l a t i o no f
VEGFR-2 Y951 was greatly reduced in the preeclamp-
tic placenta compared to gestationally-matched, nor-
mal placenta (Figure 5c). Together, these findings
indicate that increased levels of sFlt-1 have a negative
effect on VEGFR-2 tyrosine phosphorylation, which in
turn would lead to concomitant inhibition of down-
stream function and signaling and compromise mater-
nal vascular homeostasis and placental angiogenesis.
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Figure 4 Loss of sFlt-1 enhances angiogenesis and eNOS phoshorylation. (a) VEGF (20 ng/ml) induced an increase in cell migration of
HUVEC transfected with sFlt-1 siRNA compared with control siRNA using a modified Boyden chamber assay. (b) VEGF-induced capillary-like tube
formation and (c) quantification of mean total tube length per field of view after six hours treatment in HUVEC transfected with sFlt-1 siRNA or
control. (d) Representative Western blot showing eNOS phosphorylation at serine 1177 (p-eNOS (S1177)) in HUVEC transfected with soluble (sFlt-
1) or control siRNA. b-actin was used as a loading control. Data are expressed as mean (± SEM) or representative of three or more independent
experiments performed in triplicate. **P < 0.01 vs. control.
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Endothelial cell sFlt-1 expression is regulated by VEGF
and sFlt-1 is an autocrine regulator of endothelial cell
function.
Abbreviations
EGF: epidermal growth factor; eNOS: endothelial nitric oxide synthase; ERK-
1/-2: extracellular signal regulated kinase -1/2; HUVEC: human umbilical vein
endothelial cells; MAPK: mitogen activated kinase; NO: nitric oxide; PI3K:
phosphoinositide-3’-kinase; PlGF: placenta growth factor; PTEN: Phosphatase
and Tensin homolog deleted on chromosome Ten; sFlt-1: soluble vascular
endothelial growth factor receptor-1; VEGF-A: vascular endothelial growth
factor-A; VEGFR-1: vascular endothelial growth factor receptor-1; VEGFR-2:
vascular endothelial growth factor receptor-2.
Acknowledgements and funding
This work was supported by grants from the Medical Research Council
(G0600270, G0601295 and G0700288) and British Heart Foundation (RG/09/
001/25940 and PG/06/114).
Author details
1University/BHF Centre for Cardiovascular Science, Queen’s Medical Research
Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, EH16
4TJ, UK.
2Department of Reproductive and Vascular Biology, Institute for
Biomedical Research, College of Medical and Dental Sciences, University of
Birmingham, B15 2TT, UK.
Authors’ contributions
SA, MJC, PWH, BA, SS and TF performed the experiments and analysed the
data SA PWH and MJC contributed to the writing of the manuscript. AA
designed experiments and wrote the manuscript. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 4 April 2011 Accepted: 13 July 2011 Published: 13 July 2011
References
1. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor
induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature
1992, 359:843-845.
2. Dor Y, Camenisch TD, Itin A, Fishman GI, McDonald JA, Carmeliet P,
Keshet E: A novel role for VEGF in endocardial cushion formation and its
potential contribution to congenital heart defects. Development 2001,
128:1531-1538.
3. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors.
Nat Med 2003, 9:669-676.
Control EGF
0
50
100
150
200
250
300
LacZ
EGDR
Y951F
p<0.001
T
o
t
a
l
 
N
O
 
R
e
l
e
a
s
e
(
n
m
/
w
e
l
l
)
pVEGFR-2 (Y951)
-actin
CMV sFlt-1
VEGFR-2
230
kDa
47
230
Pre-term PE
pVEGFR-2 (Y951)
a b
c
Figure 5 Excess sFlt-1 inhibits VEGF receptor phosphorylation at tyrosine 951. (a) Nitric oxide (NO) release from HUVEC overexpressing
chimeric EGF receptor/VEGFR-2 constructs (EGDR) and EGDR with a mutated Y951 (Y951F), following stimulation with EGF (10 ng/ml) for one
hour. NO was measured in cell supernatants using a Sievers chemiluminescent NO analyzer and background subtracted. (b) Western blot
showing VEGFR-2 and VEGF-2 phosphorylation at tyrosine 951 (p-VEGFR-2 (Y951)) in HUVEC infected with an adenovirus encoding sFlt-1 (sFlt1)
or control virus (CMV). b-actin was used as a loading control. (c) Representative immunohistochemical staining for p-VEGFR-2 (Y951) in
gestationally-matched normal (pre-term) and preeclamptic (PE) placenta. Data are expressed as mean (± SEM) or representative of three or more
independent experiments performed in triplicate.
Ahmad et al. Vascular Cell 2011, 3:15
http://www.vascularcell.com/content/3/1/15
Page 7 of 84. Giordano FJ, Gerber HP, Williams SP, VanBruggen N, Bunting S, Ruiz-
Lozano P, Gu Y, Nath AK, Huang Y, Hickey R, et al: A cardiac myocyte
vascular endothelial growth factor paracrine pathway is required to
maintain cardiac function. Proc Natl Acad Sci USA 2001, 98:5780-5785.
5. Oosthuyse B, Moons L, Storkebaum E, Beck H, Nuyens D, Brusselmans K,
Van Dorpe J, Hellings P, Gorselink M, Heymans S, et al: Deletion of the
hypoxia-response element in the vascular endothelial growth factor
promoter causes motor neuron degeneration. Nat Genet 2001,
28:131-138.
6. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP,
Appelmans S, Oh H, Van Damme P, Rutten B, Man WY, De Mol M, et al:
Treatment of motoneuron degeneration by intracerebroventricular
delivery of VEGF in a rat model of ALS. Nat Neurosci 2005, 8:85-92.
7. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M,
Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, et al: Abnormal blood
vessel development and lethality in embryos lacking a single VEGF
allele. Nature 1996, 380:435-439.
8. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-
Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality
induced by targeted inactivation of the VEGF gene. Nature 1996,
380:439-442.
9. Miquerol L, Langille BL, Nagy A: Embryonic development is disrupted by
modest increases in vascular endothelial growth factor gene expression.
Development 2000, 127:3941-3946.
10. Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K,
Hou X, Nagai Y, Hasegawa M, et al: Angiogenic gene therapy for
experimental critical limb ischemia: acceleration of limb loss by
overexpression of vascular endothelial growth factor 165 but not of
fibroblast growth factor-2. Circ Res 2002, 90:966-973.
11. Vajanto I, Rissanen TT, Rutanen J, Hiltunen MO, Tuomisto TT, Arve K,
Narvanen O, Manninen H, Rasanen H, Hippelainen M, et al: Evaluation of
angiogenesis and side effects in ischemic rabbit hindlimbs after
intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J
Gene Med 2002, 4:371-380.
12. Carmeliet P: VEGF gene therapy: stimulating angiogenesis or angioma-
genesis? Nat Med 2000, 6:1102-1103.
13. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM: VEGF
gene delivery to myocardium: deleterious effects of unregulated
expression. Circulation 2000, 102:898-901.
14. Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM: VEGF gene delivery
to muscle: potential role for vasculogenesis in adults. Mol Cell 1998,
2:549-558.
15. Ahmad S, Ahmed A: Elevated placental soluble vascular endothelial
growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res
2004, 95:884-891.
16. Kendall RL, Wang G, Thomas KA: Identification of a natural soluble form
of the vascular endothelial growth factor receptor, FLT-1, and its
heterodimerization with KDR. Biochem Biophys Res Commun 1996,
226:324-328.
17. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor.
Potentiation of vascular endothelial growth factor bioactivity, in vitro
and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol
Chem 1994, 269:25646-25654.
18. Roeckl W, Hecht D, Sztajer H, Waltenberger J, Yayon A, Weich HA:
Differential binding characteristics and cellular inhibition by soluble
VEGF receptors 1 and 2. Exp Cell Res 1998, 241:161-170.
19. Ahmad S AA: Regulation of soluble VEGFR-1 by VEGF and oxygen and its
elevation in pre-eclampsia and fetal growth restriction. Placenta 2001,
22(A7), (Editor ed.^eds.), City.
20. Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K,
Damsky C, Fisher SJ: Vascular endothelial growth factor ligands and
receptors that regulate human cytotrophoblast survival are dysregulated
in severe preeclampsia and hemolysis, elevated liver enzymes, and low
platelets syndrome. Am J Pathol 2002, 160:1405-1423.
21. Vuorela P, Helske S, Hornig C, Alitalo K, Weich H, Halmesmaki E: Amniotic
fluid–soluble vascular endothelial growth factor receptor-1 in
preeclampsia. Obstet Gynecol 2000, 95:353-357.
22. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF,
Thadhani R, Sachs BP, Epstein FH, et al: Circulating angiogenic factors and
the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
23. Ahmed A, Dunk C, Kniss D, Wilkes M: Role of VEGF receptor-1 (Flt-1) in
mediating calcium-dependent nitric oxide release and limiting DNA
synthesis in human trophoblast cells. Lab Invest 1997, 76:779-791.
24. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA,
Morgan JP, Sellke FW, Stillman IE, et al: Excess placental soluble fms-like
tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction,
hypertension, and proteinuria in preeclampsia. J Clin Invest 2003,
111:649-658.
25. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N,
Nagy A, Roos KP, Iruela-Arispe ML: Autocrine VEGF signaling is required
for vascular homeostasis. Cell 2007, 130:691-703.
26. Bussolati B, Dunk C, Grohman M, Kontos CD, Mason J, Ahmed A: Vascular
endothelial growth factor receptor-1 modulates vascular endothelial
growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001,
159:993-1008.
27. Tseng JF, Farnebo FA, Kisker O, Becker CM, Kuo CJ, Folkman J, Mulligan RC:
Adenovirus-mediated delivery of a soluble form of the VEGF receptor
Flk1 delays the growth of murine and human pancreatic
adenocarcinoma in mice. Surgery 2002, 132:857-865.
28. Cai J, Ahmad S, Jiang WG, Huang J, Kontos CD, Boulton M, Ahmed A:
Activation of vascular endothelial growth factor receptor-1 sustains
angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase
pathway in endothelial cells. Diabetes 2003, 52:2959-2968.
29. Bergmann A, Ahmad S, Cudmore M, Gruber AD, Wittschen P,
Lindenmaier W, Christofori G, Gross V, Gonzalves A, Grone HJ, et al:
Reduction of circulating soluble Flt-1 alleviates preeclampsia-like
symptoms in a mouse model. J Cell Mol Med 2010, 14:1857-1867.
30. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K,
Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A: Negative
regulation of soluble Flt-1 and soluble endoglin release by heme
oxygenase-1. Circulation 2007, 115:1789-1797.
31. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A,
Kellems RE, Xia Y: Angiotensin II induces soluble fms-Like tyrosine kinase-
1 release via calcineurin signaling pathway in pregnancy. Circ Res 2007,
100:88-95.
32. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A:
Rational siRNA design for RNA interference. Nat Biotechnol 2004,
22:326-330.
33. Ahmad S, Hewett PW, Wang P, Al-Ani B, Cudmore M, Fujisawa T, Haigh JJ,
le Noble F, Wang L, Mukhopadhyay D, Ahmed A: Direct evidence for
endothelial vascular endothelial growth factor receptor-1 function in
nitric oxide-mediated angiogenesis. Circ Res 2006, 99:715-722.
34. Al-Ani B, Hewett PW, Cudmore MJ, Fujisawa T, Saifeddine M, Williams H,
Ramma W, Sissaoui S, Jayaraman PS, Ohba M, et al: Activation of
proteinase-activated receptor 2 stimulates soluble vascular endothelial
growth factor receptor 1 release via epidermal growth factor receptor
transactivation in endothelial cells. Hypertension 2010, 55:689-697.
35. Huang J, Kontos CD: PTEN modulates vascular endothelial growth factor-
mediated signaling and angiogenic effects. J Biol Chem 2002,
277:10760-10766.
36. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric oxide
production contributes to the angiogenic properties of vascular
endothelial growth factor in human endothelial cells. J Clin Invest 1997,
100:3131-3139.
37. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M,
Chen D, Symes JF, Fishman MC, et al: Nitric oxide synthase modulates
angiogenesis in response to tissue ischemia. J Clin Invest 1998,
101:2567-2578.
38. Kroll J, Waltenberger J: VEGF-A induces expression of eNOS and iNOS in
endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun
1998, 252:743-746.
doi:10.1186/2045-824X-3-15
Cite this article as: Ahmad et al.: Autocrine activity of soluble Flt-1
controls endothelial cell function and angiogenesis. Vascular Cell 2011
3:15.
Ahmad et al. Vascular Cell 2011, 3:15
http://www.vascularcell.com/content/3/1/15
Page 8 of 8